Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil DDI and PD Interaction Study with Midazolam
NCT02254759Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of basmisanil in Down syndrome and schizophrenia (5 arms), sponsored by Roche. Primary endpoints: Bioavailability of Drug (F) for Oral Midazolam at Day 18, Total Plasma Clearance (CL) for IV Midazolam at Day 17 and 2 more. Started Oct 2014; status: completed.
02
Drugs
basmisanil
03
Conditions
Down syndromeschizophrenia
Beyond the preview
Go deeper on NCT02254759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254759.